Capillarization of the sinusoid impedes the clearance of neurotoxic substances in liver fibrosis. These events may result in hepatic encephalopathy. Neurological and hepatic features of rats after bile duct ligation (BDL) supplemented with Manganese (BDL+Mn 2+ ) were examined. The 4-week-old BDL rats had elevated levels of ammonia and were concomitantly fed with 1 mg ml À1 of MnCl 2 in drinking water (BDL/Mn +2 ). Five out of fifteen rats were killed and the serum, liver and brain tissue (striatum and substantia nigra) were recovered. Of the remaining BDL/Mn +2 -cirrhotic animals (n¼10), five were injected with a combination of Adenovirus-human plasminogen activator (Ad-huPA) and Adenovirus-matrix metalloproteinase-8 (Ad-MMP-8) (3Â10 11 +1.5Â10 11 vector particles per kg), and five with 4.5Â10 11 vector particles per kg of Adenovirus-b-galactosidase (Ad-b-Gal). This treatment was carried on for 10 days. The BDL/Mn +2 rats displayed tremor, rigidity and gait abnormalities, which improved notably with combinatorial gene therapy, as well as motor coordination. Liver fibrosis was evidently less after treatment with Ad-huPA+Ad-MMP-8 (25%). In the brain (striatum), Ad-huPA+Ad-MMP-8 treatment rendered higher concentrations of dopamine compared with Ad-b-Gal-treated encephalopathic rats (210 and 162 ng g À1 of tissue, respectively). The BDL/Mn +2 animals and controls treated with Ad-b-Gal showed abnormal morphology in astrocytes (gliosis) in striatum and substantia nigra, in which expressions of green fibrillar acidic protein and tyrosine hydroxylase were altered. These abnormalities decreased with Ad-huPA+Ad-MMP-8 treatment. Importantly, the latter animals showed an increment in sprouting of nervous fibers in substantia nigra. Combinatorial gene therapy improves neuroanatomical and neurochemical characteristics similar to human hepatic encephalopathy.
INTRODUCTION
We have previously provided evidence that gene therapy with urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-8 (MMP-8) separately rendered improvement in liver cirrhosis. [1] [2] [3] We know that uPA is a potent liver-regeneration stimulator, whereas MMP-8 regulates the degradation of excessive matrix deposition. In this study, we combined both functional activities to elucidate whether the combinatorial effect of the two genes might render additional functions on liver fibrosis regression and one of its most serious, difficult-to-treat complications, that is, hepatic encephalopathy (HE). Recently, and in the same line of reasoning, Tucker et al. 4 showed that in Alzheimer's disease uPA inhibits b-amyloid neurotoxicity through plasminogen.
Hepatic encephalopathy is a major and common clinical complication of long-term cirrhosis. Among the main features observed are motor deficit, rigidity, sleep disturbances, psychiatric condition such as anxiety and depression, asterixis (flapping tremor) and poor muscular coordination. 5, 6 Because of the similarities in symptoms, HE is thought to involve an extrapyramidal syndrome similar to
Parkinson's disease that shows depletion of dopamine in basal ganglia, mainly at striatal level. 6 There are different metabolic routes involved in HE pathogenesis. 5, 6 One of these routes studied here is the nigrostriatal pathway that governs dopaminergic system involved in motor behavior, which is altered in neurotoxicity related with HE. Encephalopathic rats treated with combinatorial gene therapy, as shown here, underwent an improvement in dopamine depletion.
Normal brain functioning depends on several aspect of normal liver functioning. For example, the liver supplies certain nutrients to the brain that the brain itself cannot produce. Furthermore, the liver cleans the blood of neurotoxins that can damage brain cells. These substances; which include ammonia, manganese (Mn 2+ ) and other chemicals, can enter the brain, at least to some extent, unless they are effectively removed from the blood by the liver. 5 In addition to ammonia as neurotoxic agent, levels of Mn 2+ become elevated in the brain in HE. [6] [7] [8] Recent studies have shown excellent correlation between the blood and brain tissue levels of Mn 2+ with pallidal hyperintensity in magnetic resonance imaging studies. Mn 2+ is obtained physiologically from food and excess is excreted through the biliary route. The mechanism of neurotoxicity by Mn 2+ in HE is still unknown, although dopaminergic dysfunction is thought to be a possible mechanism. 8 Researchers and physicians are exploring various approaches to prevent HE in patients with chronic liver failure or to ameliorate its consequences. These approaches include: (a) strategies to lower ammonia level (lactulose, neomycin, sodium benzoate and L-ornithine L-aspartate), neuropharmacology strategies (using neuroactive drugs), liver-assisted devises or 'artificial livers' or liver transplantation. 5, [7] [8] [9] [10] [11] In this study, as a way to mimic human HE, Mn +2 was added as a precipitant factor to overt encephalopathy in bile duct-ligated (BDL) rats, which already had elevated ammonia levels.
Several approaches have been reported in experimental animals to induce hepatic regeneration and prevent the progression of liver fibrosis, or to reverse advanced liver fibrosis with gene therapy. [10] [11] [12] [13] [14] [15] The goal of this study was to search for therapeutical effect of combinatorial gene therapy using combined Adenovirus-human plasminogen activator plus Adenovirus-matrix metalloproteinase-8 (Ad-huPA plus Ad-MMP-8) on liver fibrosis regression and its consequence in HE.
RESULTS
All BDL rats concomitantly treated with Mn 2+ (BDL/Mn 2+ ) showed signs of HE, such as bristly hair, gait abnormalities (tremor, rigidity) and hind limb ataxia. The animals showed biochemical and morphological changes with extensive proliferation of bile ducts, enlarged portal tracts, inflammation, necrosis and formation of periportal fibrosis with pericentral collagen deposition, which were evident after being deprived of gene therapy treatment for 4 weeks.
Combined gene therapy treatment rendered a conspicuous reduction of hepatic fibrosis, resulting in morphological improvement.
Furthermore, these findings were accompanied by a clear improvement in collateral circulation and gastric varices, suggesting diminished intrahepatic blood pressure in animals injected with Ad-huPA plus Ad-MMP-8. In addition, an important rearrangement of the hepatic architecture was evident along with diminished inflammatory cells and decreased bile duct proliferation (data not shown). Table 1 illustrates hepatic functional tests (U l À1 ) and the expression (pg ml À1 ) of huPA and MMP-8. Notably, alanine transaminase level decreased by 90% and aspartate transaminase level decreased by 70% in Ad-huPA plus Ad-MMP-8-treated animals as compared with encephalopathic animals (BDL/Mn 2+ ) treated with Adenovirus-bgalactosidase (Ad-b-Gal). Expression of corresponding human uPA and MMP-8 proteins were detected in rat liver tissue extracts. The differential amount of these human proteins present in the livers of rats injected with Ad-huPA plus Ad-MMP-8 is evidence of the successful transduction of rat livers with both adenovectors.
Hepatic fibrosis in rats resulted in morphological changes in liver tissue comparable with those seen in human biliary fibrosis. This BDL model of extrahepatic cholestasis due to prolonged obstruction of bile flow, led to anatomic destruction of the biliary tree. However, a matching lot of cirrhotic rats otherwise treated with one single injection of 3Â10 11 viral particles plus 1.5Â10 11 viral particles (Ad-huPA plus Ad-MMP-8, respectively) showed histological improvement. Computer-assisted morphometric analysis (%) of liver slides stained with Masson trichromic and Sirius Red (fibrotic analysis) showed that combined gene therapy-treated rats had a 25% reduction in hepatic fibrosis at day 10 (Table 2) . Similarly, biochemical determinations of hydroxyproline (mg of HyP per g of tissue) demonstrated to be significantly lower in therapeutic gene-treated rat livers, corroborating and extending our findings. Quantitative data show that animals injected with Ad-b-Gal did not show a reduction in either liver fibrosis or cell necrosis. Control cirrhotic animals (BDL/Mn 2+ ) showed only a negligible decrease in fibrosis.
We also provide mechanistic insights on gene expression analysis (relative units) for collagen type I and transforming growth factor-b1 (TGF-b1) ( Table 2 ). Liver samples from Ad-huPA+Ad-MMP-8-treated BDL/Mn 2+ encephalopathic rats had decreased mRNA levels for both genes. An important rearrangement of the hepatic parenchyma was noted, along with the presence of hyperchromatic nuclei reflecting brisk liver cell regeneration. Those latter findings were confirmed by gene expression (relative units) for hepatocyte growth factor and c-met by real-time RT-PCR analysis. The gene expression of HGF and c-met was upregulated in the cirrhotic rats (BDL/Mn 2+ ) treated with combined gene therapy, but not in Ad-b-Gal-treated cirrhotic animals. These data correlate with the results obtained in the huPA plus MMP-8 in hepatic encephalopathy FJ Gálvez-Gastélum et al immunohistochemical analysis (Table 3) , in which an increase in proliferating cell nuclear antigen-and HGF-positive cells indicates cell proliferation. A concomitant decrease was observed in the number of TGF-b1-positive cells in the Ad-MMP-8+Ad-HuPA group after 10 days of treatment. Animals treated with combined gene therapy were subjected to a motor coordination test according to Jover et al. 17 All 100% of the BDL/Mn 2+ animals (n¼9) treated with the irrelevant vector displayed no improvement at all in the features measured by the behavior test. It was clear that those animals had no improvement in HE.
However, 60% of animals treated with combinatorial therapeutic gene therapy displayed an improvement in symptoms of HE, such as gait abnormalities (tremor, rigidity) and hind limb ataxia.
The Mn 2+ levels in the blood and brain were increased in cirrhotic animals treated with 1 mg ml À1 of Mn 2+ , but the animals injected with combined gene therapy had decreased amount of Mn 2+ , indicating elimination in the brain (31%) and blood (28%) (Figure 1a) .
After 4 weeks of treatment, Mn 2+ did not affect striatal dopamine levels in control (sham-operated) rats. In contrast, cirrhotic rats (BDL/Mn 2+ ) presented a decrease in striatal dopamine (30%) and the results were statistically significant when compared with sham group, indicating an accelerated turnover in dopamine metabolism. This accelerated dopamine turnover did tend to reduce in cirrhotic animals (BDL/Mn 2+ ) treated with Ad-huPA plus Ad-MMP-8, reflecting an increased dopamine concentration in striatum as compared with irrelevant control (Ad-b-Gal) (Figure 1b) .
Our major thrust in this study was to establish the potential improvement in HE after treatment with combinatorial gene therapy. Thus, we looked for reactivity to tyrosine hydroxylase (TH) and observed that neurons in substantia nigra were strongly TH-positive, characteristically pyramidal and bipolar with their prolongations and dendritic spines well-defined (arrows) in the normal group Table 3 Immunohistochemical assay Notably, disrupted fibers were also evident. The BLD/Mn 2+ animals treated with Ad-MMP-8 showed morphological characteristics of pyramidal neurons and the disrupted fibers were observed to be similar to those of Ad-huPA-treated rats, but the nucleous was less clear and the sprouting was more evident (arrows) (Figures 2j-l) . However, those animals treated with combinatorial gene therapy (Ad-huPA plus Ad-MMP-8) had and important recovery and/or protective effect in their TH-positive neurons (asterisks). Those nervous cells showed an increase in their dendritic prolongations (arrows) and sprouting with major integrity resulting in improvement of neuronal morphology and structure, suggesting a better functionality in dopaminergic neurotransmission (Figures 2m-o) . These results highlight the additive effect of both human proteins in the Another striking finding in BDL/Mn 2+ encephalopathic rats was an increased number of astrocytic cells (gliosis) ( Table 4 ). This table represents a quantitative analysis of glial fibrillary acidic protein (GFAP)-positive astrocytes with an important number of astrocytes with less gene expression of GFAP only in the animals treated with combined gene therapy.
Morphological analysis of cytoplasmic ramifications indicated that HE produced greater complexity, manifested by an increased in size, volume and number of cytoplasmic intersections, indicating a persistent reactive astrocytic and hyperplasia response, characteristic of a neurotoxic lesion of this brain area. Most of the astrocytes from encephalopathic rats treated with Ad-b-Gal were markedly swollen. On rats in Ad-huPA group, the volume and number of cytoplasmic intersections, as well as their morphological characteristics of astrocytes were decreased with respect to Ad-b-Gal and control group. On the other side, rats in Ad-MMP-8 group showed an important loss in number of GFAPpositive astrocytes cell. Finally, in the combined gene therapy group, a reduced number in GFAP-positive astrocytes was observed, along with similarities with control group regarding morphological characteristics in size and intersections. Evidently, these facts were different from the findings shown with Ad-GFP, which indicates an important response of the astrocytes to the combined gene therapy.
DISCUSSION
The onset of neuropsychiatric symptoms in HE is often insidious, starting with changes in personality and alterations in sleep patterns. Shortened attention span and lack of muscular coordination including asterixis (flapping tremor) follow, progressing eventually through lethargy to stupor. Motor signs including rigidity are not uncommon. 5, 9 Accumulation of several neurotoxic substances has been reported and it is likely that many of them contribute to pathogenesis of HE. Importantly, Mn 2+ has been suggested recently as a candidate substance. 16 Potential mechanisms responsible for Mn 2+ overload include a decrease in elimination through biliary excretion, and an increased systemic availability due to transferrin-dependent mechanism and portosystemic shunting. 6, 16 Then, it is well-established that substances, such as Mn 2+ , other than ammonia are implicated in the pathogenesis of HE in cirrhosis. 17 In this study, Mn 2+ was added in the drinking water of BDL rats, which already had elevated blood ammonia levels, as a precipitant factor to overt encephalopathy in rats as a way to mimic HE that occurs in humans.
Cirrhosis is characterized with a variable degree of cholestasis that can diminish biliary Mn 2+ excretion. In addition, abnormalities of microcirculation (capillarization of the sinusoids and/or intrahepatic shunting) are present in cirrhotic livers. 16 As demonstrated in our experimental model for HE, 4 weeks of biliary obstruction increased the brain and blood Mn 2+ content. 6 This increased Mn 2+ accumulation was diminished in animals treated with Ad-huPA plus Ad-MMP-8, indicating Mn 2+ depuration after liver fibrosis regression (Figure 1a) . Although simplistic, one plausible explanation is that brain toxicity improves as first extracellular matrix gets degraded and liver regeneration takes place by the strong combined action of the two-adenoviral vector used. These events would render a greater depuration of blood-and brain-toxic substances, including Mn 2+ .
Astrocytes in HE brains exhibit large swollen nuclei with margination of the chromatin pattern, resulting in a large pale nucleus and prominent nucleolus. 5, 9 These cells localized in the striatal region participate in the elimination of neurotoxic molecules. When activated, these cells increase in size, number and present a number of cytoplasmic intersections, indicating a persistent reactive astrocytic and hyperplasia response characteristic of a neurotoxic lesion of striatal region (gliosis) ( Table 4 ). This astrocyte activation is characterized by GFAP upregulation as bonafide marker. As shown in this study, treatment with combinatorial gene therapy resulted in an important decrease in gliosis, as well as in GFAP expression, indicating a substantial improvement in brain detoxification, probably by hepatic Mn 2+ depuration.
However, non-treated encephalopathic animals displayed a diminution in dopamine concentration, which is consistent with results observed in cirrhotic patients. This is due to dopamine-accelerated metabolism and also due to a decrease in rate-limiting dopaminesynthesizing enzymes, that is, tyrosine hydroxilase and monoamine oxidase. Gene therapy used here demonstrated to be beneficial in terms of dopamine levels recovery in the striatal region.
Substantia nigra is the brain region in which the main dopaminergic pathway supplies dopamine to the striatum. Therefore, in our encephalopathic animals there was consequently low TH levels in tissue slices showing sustantia nigra (Figure 2) . Our results shown here, demonstrated that combinatorial gene therapy induced an important recovery and/or protection in TH-positive neurons. We are now pursuing the mechanism by which, in our gene therapytreated animals, TH expression bounces back nearly reaching normal expression (Figure 2) . It is possible too, that adenoviral vectors could pass the blood-brain barrier and could influence the positive recovery of TH-positive neurons. Recently, it has been shown that uPA has a positive impact on brain toxicity by b-amyloid. 4 Taken together, it is clear that events resulting in liver fibrosis regression have a definitive impact in improvement in brain function in encephalopathic animals.
A growing body of evidence suggests that application of gene therapy strategies seem promising and plausible therapeutic measures for a number of pathophysiological conditions. Recent reports describe that transduction efficiency by adenoviral-mediated gene transfer reduced after liver injury, but remained significant. 12 As documented in previous studies, the administration of adenovirus is an effective means to direct transgene expression in liver as assessed by visual detection of transduced GFP or b-Gal (data no shown). However, compared with normal controls, transgene expression as assessed by the delivery of an Ad-GFP or Ad-b-Gal reporter was significantly reduced in BDL/Mn 2+ cirrhotic rats. 12 Several gene therapy approaches have successfully prevented and halted the progression of liver fibrosis in experimental models. However, because fibrotic liver disease may not be clinically detected until an advanced stage with concomitant appearance of disturbances in the central nervous system, that is, HE, the possibility of reversing established fibrosis becomes an essential issue. 13 Immunohistochemical analyses demonstrated the presence of TGF-b1-positive cells widely distributed in the livers of BDL/Mn 2+ -treated rats. Ad-huPA plus Ad-MMP-8 injection substantially decrease the number of TGF-b1-positive cells. Consistent with this, the level of TGF-b1 and Collagen type I mRNA's expression was reduced by the treatment with combined gene therapy. huPA plus MMP-8 in hepatic encephalopathy FJ Gálvez-Gastélum et al
Hepatocyte growth factor is suggested to be the major activator of hepatic regeneration, although uPA is also important in the early stages of hepatic regeneration. 15 In this study, quantitative analysis of hepatic regeneration showed a high level of mRNA expression for HGF and c-met in cirrhotic livers (BDL/Mn 2+ ) treated with Ad-huPA plus Ad-MMP-8. We also examined the effect of gene therapy on hepatocyte proliferation by immunohistochemistry for HGF and proliferating cell nuclear antigen, corroborating and extending our results at the protein level.
Finally, the fact that BDL/Mn 2+ rats treated with therapeutic adenovectors displayed a marked improvement in behavior studies, specifically in a motor coordination test, is encouraging.
These results suggest that advanced hepatic fibrosis or cirrhosis regression is impacting positively, and therefore, liver cell proliferation, stabilization of functional hepatic tests, disappearance of abnormal gastric circulation and ascites, renders improvement of HE.
MATERIALS AND METHODS

Adenoviral vectors
Adenoviral (Ad) plasmid pAd: PGKDNDC-huPA (pAd-DhuPA) cloning has been described previously and is essentially a first-generation Ad vector bearing a modified complementary DNA coding for nonsecreted human urokinase plasminogen activator (Ad-huPA). 18 Preparations of this Ad vector were monitored for endotoxin and mycoplasm contaminants and were titered as previously described. 19 pAdHM2-MMP-8 an DE1, DE3 adenoviral plasmid vector expressing the proenzyme of human MMP-8 under the control of the cytomegalovirus promoter (pCMV) and with a simian virus 40 polyadenylation signal, was constructed by an in vitro ligation method according to the method described below. 20 The expression cassette coding for MMP-8 was excised with NruI/ScaI from plasmid pcDNA-MMP-8 and inserted into the SmaI site of the multiple cloning site of the shuttle plasmid pHM3, and the resulting plasmid, pHM3-MMP-8, was digested with I-CeuI and PI-SceI. The released fragment was ligated with I-CeuI/PI-SceI-digested plasmid pAd-HM2, which contains the DE1-DE3 adenovirus type 5 genome. 21 The resulting ligation product was transformed into ultracompetent DH5a, and recombinant clones were isolated by ampicillin selection and screened by restriction analysis.
The Ad5-b-Gal vector used here as an irrelevant control, is a first-generation E1-and E3-deleted replication-defective adenovirus vector that has been described previously. 20 
Experimental model
Wistar female rats were housed in the animal facility at University of Guadalajara and all animal studies were conducted in accordance with the principles and procedures outlined in the National Institutes of Health's Guide for the Care and Use of Laboratory Animals. Rats weighing 200-250 g were anesthetized with ethyl ether, and the common bile duct was exposed, ligated and excised for 4 weeks to induce biliary fibrosis (extrahepatic cholestasis) according to the method of Lee et al. 22 After surgery, the animals had free access to food (Rodent Laboratory Chow* 5001, LabDiet, Richmond, IN, USA) and to 1 mg ml À1 of MnCl 2 (Sigma-Aldrich, St Louis, MO, USA) in drinking water (BDL/Mn 2+ ). Five rats were sham-operated at the same time and used as controls. After this point, five animals (BDL/Mn 2+ ) were killed and the blood, liver and brain tissue (striatum) were obtained. Of the remaining BDL/Mn 2+ -cirrhotic animals (n¼18), nine were injected with Ad-huPA plus Ad-MMP-8 (3Â10 11 +1.5Â10 11 vector particles per kg, respectively) and the remaining rats were injected with Ad-b-Gal (4.5Â10 11 vector particles per kg) via iliac vein; notably, the amount of vector particles per kg is the same for 'therapeutic' vectors and for irrelevant adenovectors (Ad-b-Gal). After 10 days, five cirrhotic animals injected with combined gene therapy and five cirrhotic animals treated with Ad-b-Gal were killed, decapitated and biological specimens were obtained (all biological samples were deposited on freeze-CO 2 ). The remaining animals were perfused with 180 ml of 0.9% NaCl containing 10 U ml À1 heparin for approximately 2 min at room temperature. This was followed by perfusion with 280 ml 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 10 min at a pressure of 140 cm H 2 O. The brain was removed by craniotomy to be additionally fixed by immersion in the same fixative solution. Coronal slices (striatum and substantia nigra) were cut in 4-mm-thick sections for immunohistochemistry procedures.
Hepatic functional test
The blood (1.5 ml) was drawn from animals and serum alanine transaminase and aspartate transaminase levels were determined in an automated Sincron-7 analyzer at Hospital Civil de Guadalajara. Five animals were studied in each group.
Histological analysis
The liver samples were fixed by immersion in 4% paraformaldehyde diluted in phosphate-buffered saline, dehydrated in graded ethyl alcohol and embedded in paraffin. Briefly, 5-mm-thick sections were stained with hematoxylin/eosin, Sirious Red and Masson trichromic to determine amount of liver tissue affected by extracellular matrix. Then, by using a computer-assisted automated image analyzer (Leica QWin, Leica Microsystems, Wetzlar, Germany) 20 random fields per slide were analyzed and the ratio of connective tissue to the whole area of the liver was calculated.
Biochemical determinations of hydroxyproline content
The liver samples were obtained at the moment of death, and 150 mg was subjected to acid hydrolysis with 6 N HCl to determine the amount of hydroxyproline according to the method of Rojkind and Gonzalez. 23 
Real-time RT-PCR
A total of 2 mg of total RNA was incubated with 1 U of ribonuclease-free deoxiribonuclease-I at 37 1C for 30 min, and the reaction was terminated by the addition of 50 mmol l À1 EDTA and heating at 75 1C for 10 min. Samples were incubated with 0.5 mg of oligo(dT) primer at 70 1C for 10 min and subjected to 100 U of Moloney murine leukemia virus reverse transcriptase (RT) for 50 min at 37 1C. Complementary DNA was sintetized from livers of control and experimental animals to conduct real-time PCR assay kits for TGF-b1, Collagen I, HGF and c-met. TaqMan probes (Applied Biosystems, Carlsbad, CA, USA) were used for the quantification of expression of these genes in a rotor gene RG-3000 instrument (Qiagen, Valencia, CA, USA). Housekeeping gene, rat GADPH (Applied Biosystems) was used to normalize the measurement using DDC t method.
Liver immunohistochemistry
The liver tissues were fixed in 4% paraformaldehyde and embedded in paraffin and 5-mm sections were mounted in silane-covered slides and deparaffinized, and the endogenous activity of peroxidase was quenched with H 2 O 2 (0.03%) in absolute methanol. The liver sections were incubated overnight at room temperature with rabbit monoclonal anti-proliferating cell nuclear antigen (anti-PCNA) (Sigma-Aldrich), anti-TGF-b (Sigma-Aldrich) and anti-HGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Bound antibodies were detected with peroxidase-labeled rabbit polyclonal antibodies against mouse or goat immunoglobulins, developed with diaminobenzidine substrate and counterstained with hematoxylin.
Behavior test
Beam-walking test was used to determine motor coordination. Coordination tests were performed in the afternoon in seven healthy, nine shams, seven sham+Mn 2+ , nine BDL+Mn 2+ rats treated with Ad-b-Gal and eight BDL+Mn 2+ rats treated with Ad-huPA plus AdMMP-8. Tests were performed at 10 days after adenoviral treatments. In the walking test, the ability of rats to pass through a narrow beam to reach a dark platform (100Â2 cm) is evaluated. The wooden square beam was elevated to a height of 1 m above the floor. In this test, the time to cross the beam and the number of forelimb and hind limb foot faults were recorded. A fault was defined as any foot slip off the top surface of the beam or any limb use on the side of the beam. The day of the test, three trials were performed before recording the results. The goal was to accustom the rats to the beam and to let them to know the existence of the dark platform at the end of the beam. The interval between trials was 5 min. 17 huPA plus MMP-8 in hepatic encephalopathy FJ Gálvez-Gastélum et al
Determination of dopamine
Left striatum of rats from all treatments groups were homogenized in 500 ml of perchloric acid-sodium metabisulfite solution 1 M (0.1%, w/v). Samples were then centrifuged at 4000 g for 10 min and supernatants were kept at À70 1C until analyzed. The striatal content of dopamine was analyzed using high performance liquid chromatography (Millipore, Billerica, MA, USA) in a C18 column (1 mm) of reversed phase and electrochemical detection (Beckman Instruments, Fullerton, CA, USA).
Neuroanatomical characterization
For quantitative morphological analyses of striatum and substantia nigra, 4-mm-thick coronal slides were cut in a vibratome. Chosen tissues were immunohistochemically processed by the free-floating procedure. Sections were incubated for 72 h with mouse anti-GFAP (Chemicon International, Billerica, MA, USA) and mouse anti-tyrosine hydroxylase monoclonal antibody (anti-TH) (Chemicon International), at a 1:1000 dilution in phosphatebuffered saline and were detected with peroxidase-labeled rabbit polyclonal antibodies against mouse immunoglobulins and diaminobenzidine and stained with hematoxylin.
Immunostained sections of substantia nigra and striarum were analyzed with light microscopy to quantify the number of TH-labeled neurons and GFAP-labeled astrocytic cells, respectively. In coronal slices of each experimental group, 20 microscopic fields were examined randomly at Â40 enlargement (0.1 mm 2 of tissue), through the complete substantia nigra region thickness. The morphological transformation of GFAP-positive astrocytes was assessed with the aid of a stereological graticule placed on the cellular soma and their cytoplasmic visible prolongations. The graticule was superimposed on the image of the GFAP-immunoreactive cells by using a microscope fitted with a camera lucida attachment. This graticule consisted of seven concentric circles with 28 mm distance between each circle; the cellular nucleus was positioned in the center of the graticule, to register the total number of sites in which the cellular prolongations intersected with the concentric lines.
Statistical analysis
Results are expressed as mean ± s.d. Analysis of variance was used. Po0.05 was considered to indicate a significant difference between groups.
